Literature DB >> 7547630

Loss of heterozygosity on the X chromosome in human breast cancer.

M L Loupart1, S Adams, J A Armour, R Walker, W Brammar, J Varley.   

Abstract

The analysis of loss of heterozygosity (LOH) in tumours can be a powerful tool for mapping the sites of tumour suppressor genes in the human genome. A panel of breast cancer patients was assembled as pairs of tumour and lymphocyte DNA samples and LOH studies carried out by Southern hybridisation with polymorphic loci mapping to the X chromosome with appropriate controls. Deletion mapping revealed a high frequency of small regionalised deletions, defining at least three independent regions, one of which is particularly well mapped to a 500 kb stretch of DNA in the distal portion of the pseudoautosomal region of Xp. A second region has been identified within the pseudoautosomal region close to the pseudoautosomal boundary, and there is a third discrete site of loss on distal Xq. Perturbations of sequences at these regions represent independent events in a number of patients. This study represents the first detailed analysis of LOH on the X chromosome in human breast tumours, the results of which indicate that at least three regions of this chromosome are involved in the disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7547630     DOI: 10.1002/gcc.2870130402

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

1.  ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway.

Authors:  Hsu-Ping Kuo; Dung-Fang Lee; Chun-Te Chen; Mo Liu; Chao-Kai Chou; Hong-Jen Lee; Yi Du; Xiaoming Xie; Yongkun Wei; Weiya Xia; Zhang Weihua; Jer-Yen Yang; Chia-Jui Yen; Tzu-Hsuan Huang; Minjia Tan; Gang Xing; Yingming Zhao; Chien-Hsing Lin; Shih-Feng Tsai; Isaiah J Fidler; Mien-Chie Hung
Journal:  Sci Signal       Date:  2010-02-09       Impact factor: 8.192

Review 2.  DNA copy number losses in human neoplasms.

Authors:  S Knuutila; Y Aalto; K Autio; A M Björkqvist; W El-Rifai; S Hemmer; T Huhta; E Kettunen; S Kiuru-Kuhlefelt; M L Larramendy; T Lushnikova; O Monni; H Pere; J Tapper; M Tarkkanen; A Varis; V M Wasenius; M Wolf; Y Zhu
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

Review 3.  Inactivation of X-linked tumor suppressor genes in human cancer.

Authors:  Runhua Liu; Mandy Kain; Lizhong Wang
Journal:  Future Oncol       Date:  2012-04       Impact factor: 3.404

4.  Extra copies of chromosomes 16 and X in invasive breast carcinomas are related to aggressive phenotype and poor prognosis.

Authors:  Lydia Nakopoulou; Effie G Panayotopoulou; Ioanna Giannopoulou; Ioanna Tsirmpa; Sophia Katsarou; Eleni Mylona; Paraskevi Alexandrou; Antonios Keramopoulos
Journal:  J Clin Pathol       Date:  2007-07       Impact factor: 3.411

5.  Expression profile of microRNAs in c-Myc induced mouse mammary tumors.

Authors:  Yuan Sun; Jack Wu; Si-hung Wu; Archana Thakur; Aliccia Bollig; Yong Huang; D Joshua Liao
Journal:  Breast Cancer Res Treat       Date:  2008-09-07       Impact factor: 4.872

6.  Human chromosome-specific aneuploidy is influenced by DNA-dependent centromeric features.

Authors:  Marie Dumont; Riccardo Gamba; Pierre Gestraud; Sjoerd Klaasen; Joseph T Worrall; Sippe G De Vries; Vincent Boudreau; Catalina Salinas-Luypaert; Paul S Maddox; Susanne Ma Lens; Geert Jpl Kops; Sarah E McClelland; Karen H Miga; Daniele Fachinetti
Journal:  EMBO J       Date:  2019-11-21       Impact factor: 11.598

7.  Characterization of ductal carcinoma in situ cell lines established from breast tumor of a Singapore Chinese patient.

Authors:  Jacklyn Wy Yong; Meng Ling Choong; SiFang Wang; Yu Wang; Shermaine Qy Lim; May Ann Lee
Journal:  Cancer Cell Int       Date:  2014-09-20       Impact factor: 5.722

8.  BCoR-L1 variation and breast cancer.

Authors:  Felicity Lose; Jeremy Arnold; David B Young; Carolyn J Brown; Graham J Mann; Gulietta M Pupo; Kum Kum Khanna; Georgia Chenevix-Trench; Amanda B Spurdle
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.